(Q36662474)

15 August 2017

1 reference

title

Drug insight: maintenance immunosuppression in kidney transplant recipients (English)

1 reference

15 August 2017

1 reference

3

Arjang Djamali

1 reference

15 August 2017

Millie Samaniego

1

1 reference

15 August 2017

Bryan N Becker

series ordinal

2

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

688-699

1 reference

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Transplantation 50 years later--progress, challenges, and promises

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Renal transplantation: a half century of success and the long road ahead.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Immunosuppressive drugs for kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Factors associated with improvement in deceased donor renal allograft function in the 1990s

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Workshop on late renal allograft dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Death after graft loss: an important late study endpoint in kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Medical care of kidney transplant recipients after the first posttransplant year

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Disease progression and outcomes in chronic kidney disease and renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Pharmacokinetic principles of immunosuppressive drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Immunosuppression: evolution in practice and trends, 1994-2004.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Immunosuppression: evolution in practice and trends, 1993-2003.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Immunosuppressive strategies in transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Current and future immunosuppressive strategies in renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Pharmacology of calcineurin antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Cyclosporine and tacrolimus-associated thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

A novel approach to the treatment of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Immunosuppression, skin cancer, and ultraviolet A radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Malignancy after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Azathioprine and UVA light generate mutagenic oxidative DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolate mofetil in solid-organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Leflunomide for polyomavirus type BK nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Treatment of renal allograft polyoma BK virus infection with leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Leflunomide therapy for cytomegalovirus disease in renal allograft recepients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Rapamycin in transplantation: a review of the evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Clinical experience with everolimus (Certican): optimizing dose and tolerability

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Clinical pharmacokinetics of everolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Testosterone concentrations and sirolimus in male renal transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Steroid withdrawal for the (selected) masses

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Pregnancy in renal transplant recipients: long-term effect on patient and graft survival. A single-center experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Anti-inflammatory and immunosuppressive drugs and reproduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0343

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0343

1 reference

15 August 2017

1 reference